She will serve as a member of REGENXBIO's Nominating and Corporate Governance Committee.
The biotech will use the funds for a slate of gene insertion programs for liver disorders out of the lab of gene therapy pioneer Jim Wilson, M.D., Ph.D. at Penn.
One of Tachi’s newly born legacy biotechs raises $135M and enlists an A-list board to advance late-stage vaccine
Tachi Yamada's biotechs are continuing to make news.
The U.S. FDA has given the first full approval to a COVID-19 mRNA vaccine, which uses modified mRNA technology invented and developed by scientists at Penn.
The Daily podcast by the New York Times interviewed Dr. Katalin Kariko about the long road to getting mRNA into the vaccines that are winning the war against COVID.
PCI’s Managing Director leads panel discussion on Cellicon Valley with Penn Medicine faculty luminaries
On May 6th, as part of the Cellicon Valley '21 two-day event, John Swartley, Managing Director of PCI, joined Penn Medicine faculty to discuss the commercialization of CAR-T technology